Gilead's $1,000-a-pill antiviral remdesivir is no wonder drug. We knew this when it failed for hepatitis, the disease it was created for. And then when it failed for Ebola. And then again, when it failed for COVID-19. But like a bolt, in late April, a breakthrough: in a second trial for COVID-19 patients, remdesivir sped time to recovery—proof of benefit,
Read more...

On April 29th Anthony Fauci announced the National Institute of Allergy and Infectious Diseases, an institute he runs, had completed a study of the antiviral remdesivir for COVID-19. The drug reduced time to recovery from 15 to 11 days, he said, a breakthrough proving "a drug can block this virus." Now people are clamoring for $1,000-a-pill remdesivir. While the results were preliminary, unpublished, and unconfirmed by ...

Read more...

In January, we learned of an emerging threat in China, a variant of the frightening SARS virus, but worse—more infectious. Since then, we learned China, the first to both see and successfully manage its outbreak, seriously under-detected the disease. According to a widely circulated computer model study, true cases were probably around seven times greater than the official count. Calculations published a ...

Read more...

1 Pages

Most Popular

✓ Join 150,000+ subscribers
✓ Get KevinMD's most popular stories